Association between human blood metabolome and the risk of breast cancer

Breast cancer is the most common cancer among women with limited treatment options. To identify promising drug targets for breast cancer, we conducted a systematical Mendelian randomization (MR) study to screen blood metabolome for potential causal mediators of breast cancer and further predict targ...

Full description

Saved in:
Bibliographic Details
Published inBreast cancer research : BCR Vol. 25; no. 1; pp. 9 - 11
Main Authors Wang, Yu, Liu, Fanghua, Sun, Lulu, Jia, Yiming, Yang, Pinni, Guo, Daoxia, Shi, Mengyao, Wang, Aili, Chen, Guo-Chong, Zhang, Yonghong, Zhu, Zhengbao
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 24.01.2023
BioMed Central
BMC
Subjects
Acetates
Acetic acid
Biobanks
Biomarkers
Blood
Breast cancer
Breast Neoplasms - etiology
Breast Neoplasms - genetics
Cancer
Cancer therapies
Care and treatment
Cholesterol
Cholesterol, HDL - genetics
Circulatory system
Clinical trials
Collaboration
Consortia
Development and progression
Disease
Female
Genome-wide association studies
Genome-Wide Association Study
Genomes
Genomics
Health aspects
High density lipoprotein
Humans
Mendelian randomization
Mental disorders
Mental illness
Metabolism
Metabolites
Metabolome
NMR
Nuclear magnetic resonance
Oncology, Experimental
Polymorphism, Single Nucleotide
Prevention
Risk Factors
Side effects
Statistical power
Therapeutic targets
Triglycerides
United Kingdom > UK
Metabolites
Breast cancer
Mendelian randomization
Online AccessGet full text

Cover

Abstract Breast cancer is the most common cancer among women with limited treatment options. To identify promising drug targets for breast cancer, we conducted a systematical Mendelian randomization (MR) study to screen blood metabolome for potential causal mediators of breast cancer and further predict target-mediated side effects. We selected 112 unique blood metabolites from 3 large-scale European ancestry-based genome-wide association studies (GWASs) with a total of 147,827 participants. Breast cancer data were obtained from a GWAS in the Breast Cancer Association Consortium (BCAC), involving 122,977 cases and 105,974 controls of European ancestry. We conducted MR analyses to systematically assess the associations of blood metabolites with breast cancer, and a phenome-wide MR analysis was further applied to ascertain the potential on-target side effects of metabolite interventions. Two blood metabolites were identified as the potential causal mediators for breast cancer, including high-density lipoprotein cholesterol (HDL-C) (odds ratio [OR], 1.09; 95% confidence interval [CI], 1.06-1.12; P = 9.67 × 10 ) and acetate (OR, 1.24; 95% CI, 1.13-1.37; P = 1.35 × 10 ). In the phenome-wide MR analysis, lowering HDL-C might have deleterious effects on the risk of the circulatory system and foreign body injury, while lowering acetate had deleterious effects on mental disorders disease. The present systematic MR analysis revealed that HDL-C and acetate may be the causal mediators in the risk of developing breast cancer. Side-effect profiles were characterized to help inform drug target prioritization for breast cancer prevention. HDL-C and acetate might be promising drug targets for preventing breast cancer, but they should be applied under weighting advantages and disadvantages.
AbstractList Breast cancer is the most common cancer among women with limited treatment options. To identify promising drug targets for breast cancer, we conducted a systematical Mendelian randomization (MR) study to screen blood metabolome for potential causal mediators of breast cancer and further predict target-mediated side effects. We selected 112 unique blood metabolites from 3 large-scale European ancestry-based genome-wide association studies (GWASs) with a total of 147,827 participants. Breast cancer data were obtained from a GWAS in the Breast Cancer Association Consortium (BCAC), involving 122,977 cases and 105,974 controls of European ancestry. We conducted MR analyses to systematically assess the associations of blood metabolites with breast cancer, and a phenome-wide MR analysis was further applied to ascertain the potential on-target side effects of metabolite interventions. Two blood metabolites were identified as the potential causal mediators for breast cancer, including high-density lipoprotein cholesterol (HDL-C) (odds ratio [OR], 1.09; 95% confidence interval [CI], 1.06-1.12; P = 9.67 x 10.sup.-10) and acetate (OR, 1.24; 95% CI, 1.13-1.37; P = 1.35 x 10.sup.-5). In the phenome-wide MR analysis, lowering HDL-C might have deleterious effects on the risk of the circulatory system and foreign body injury, while lowering acetate had deleterious effects on mental disorders disease. The present systematic MR analysis revealed that HDL-C and acetate may be the causal mediators in the risk of developing breast cancer. Side-effect profiles were characterized to help inform drug target prioritization for breast cancer prevention. HDL-C and acetate might be promising drug targets for preventing breast cancer, but they should be applied under weighting advantages and disadvantages.
Breast cancer is the most common cancer among women with limited treatment options. To identify promising drug targets for breast cancer, we conducted a systematical Mendelian randomization (MR) study to screen blood metabolome for potential causal mediators of breast cancer and further predict target-mediated side effects. We selected 112 unique blood metabolites from 3 large-scale European ancestry-based genome-wide association studies (GWASs) with a total of 147,827 participants. Breast cancer data were obtained from a GWAS in the Breast Cancer Association Consortium (BCAC), involving 122,977 cases and 105,974 controls of European ancestry. We conducted MR analyses to systematically assess the associations of blood metabolites with breast cancer, and a phenome-wide MR analysis was further applied to ascertain the potential on-target side effects of metabolite interventions. Two blood metabolites were identified as the potential causal mediators for breast cancer, including high-density lipoprotein cholesterol (HDL-C) (odds ratio [OR], 1.09; 95% confidence interval [CI], 1.06-1.12; P = 9.67 × 10 ) and acetate (OR, 1.24; 95% CI, 1.13-1.37; P = 1.35 × 10 ). In the phenome-wide MR analysis, lowering HDL-C might have deleterious effects on the risk of the circulatory system and foreign body injury, while lowering acetate had deleterious effects on mental disorders disease. The present systematic MR analysis revealed that HDL-C and acetate may be the causal mediators in the risk of developing breast cancer. Side-effect profiles were characterized to help inform drug target prioritization for breast cancer prevention. HDL-C and acetate might be promising drug targets for preventing breast cancer, but they should be applied under weighting advantages and disadvantages.
Abstract Background Breast cancer is the most common cancer among women with limited treatment options. To identify promising drug targets for breast cancer, we conducted a systematical Mendelian randomization (MR) study to screen blood metabolome for potential causal mediators of breast cancer and further predict target-mediated side effects. Methods We selected 112 unique blood metabolites from 3 large-scale European ancestry-based genome-wide association studies (GWASs) with a total of 147,827 participants. Breast cancer data were obtained from a GWAS in the Breast Cancer Association Consortium (BCAC), involving 122,977 cases and 105,974 controls of European ancestry. We conducted MR analyses to systematically assess the associations of blood metabolites with breast cancer, and a phenome-wide MR analysis was further applied to ascertain the potential on-target side effects of metabolite interventions. Results Two blood metabolites were identified as the potential causal mediators for breast cancer, including high-density lipoprotein cholesterol (HDL-C) (odds ratio [OR], 1.09; 95% confidence interval [CI], 1.06–1.12; P = 9.67 × 10−10) and acetate (OR, 1.24; 95% CI, 1.13–1.37; P = 1.35 × 10−5). In the phenome-wide MR analysis, lowering HDL-C might have deleterious effects on the risk of the circulatory system and foreign body injury, while lowering acetate had deleterious effects on mental disorders disease. Conclusions The present systematic MR analysis revealed that HDL-C and acetate may be the causal mediators in the risk of developing breast cancer. Side-effect profiles were characterized to help inform drug target prioritization for breast cancer prevention. HDL-C and acetate might be promising drug targets for preventing breast cancer, but they should be applied under weighting advantages and disadvantages.
BackgroundBreast cancer is the most common cancer among women with limited treatment options. To identify promising drug targets for breast cancer, we conducted a systematical Mendelian randomization (MR) study to screen blood metabolome for potential causal mediators of breast cancer and further predict target-mediated side effects.MethodsWe selected 112 unique blood metabolites from 3 large-scale European ancestry-based genome-wide association studies (GWASs) with a total of 147,827 participants. Breast cancer data were obtained from a GWAS in the Breast Cancer Association Consortium (BCAC), involving 122,977 cases and 105,974 controls of European ancestry. We conducted MR analyses to systematically assess the associations of blood metabolites with breast cancer, and a phenome-wide MR analysis was further applied to ascertain the potential on-target side effects of metabolite interventions.ResultsTwo blood metabolites were identified as the potential causal mediators for breast cancer, including high-density lipoprotein cholesterol (HDL-C) (odds ratio [OR], 1.09; 95% confidence interval [CI], 1.06–1.12; P = 9.67 × 10−10) and acetate (OR, 1.24; 95% CI, 1.13–1.37;P = 1.35 × 10−5). In the phenome-wide MR analysis, lowering HDL-C might have deleterious effects on the risk of the circulatory system and foreign body injury, while lowering acetate had deleterious effects on mental disorders disease.ConclusionsThe present systematic MR analysis revealed that HDL-C and acetate may be the causal mediators in the risk of developing breast cancer. Side-effect profiles were characterized to help inform drug target prioritization for breast cancer prevention. HDL-C and acetate might be promising drug targets for preventing breast cancer, but they should be applied under weighting advantages and disadvantages.
Breast cancer is the most common cancer among women with limited treatment options. To identify promising drug targets for breast cancer, we conducted a systematical Mendelian randomization (MR) study to screen blood metabolome for potential causal mediators of breast cancer and further predict target-mediated side effects.BACKGROUNDBreast cancer is the most common cancer among women with limited treatment options. To identify promising drug targets for breast cancer, we conducted a systematical Mendelian randomization (MR) study to screen blood metabolome for potential causal mediators of breast cancer and further predict target-mediated side effects.We selected 112 unique blood metabolites from 3 large-scale European ancestry-based genome-wide association studies (GWASs) with a total of 147,827 participants. Breast cancer data were obtained from a GWAS in the Breast Cancer Association Consortium (BCAC), involving 122,977 cases and 105,974 controls of European ancestry. We conducted MR analyses to systematically assess the associations of blood metabolites with breast cancer, and a phenome-wide MR analysis was further applied to ascertain the potential on-target side effects of metabolite interventions.METHODSWe selected 112 unique blood metabolites from 3 large-scale European ancestry-based genome-wide association studies (GWASs) with a total of 147,827 participants. Breast cancer data were obtained from a GWAS in the Breast Cancer Association Consortium (BCAC), involving 122,977 cases and 105,974 controls of European ancestry. We conducted MR analyses to systematically assess the associations of blood metabolites with breast cancer, and a phenome-wide MR analysis was further applied to ascertain the potential on-target side effects of metabolite interventions.Two blood metabolites were identified as the potential causal mediators for breast cancer, including high-density lipoprotein cholesterol (HDL-C) (odds ratio [OR], 1.09; 95% confidence interval [CI], 1.06-1.12; P = 9.67 × 10-10) and acetate (OR, 1.24; 95% CI, 1.13-1.37; P = 1.35 × 10-5). In the phenome-wide MR analysis, lowering HDL-C might have deleterious effects on the risk of the circulatory system and foreign body injury, while lowering acetate had deleterious effects on mental disorders disease.RESULTSTwo blood metabolites were identified as the potential causal mediators for breast cancer, including high-density lipoprotein cholesterol (HDL-C) (odds ratio [OR], 1.09; 95% confidence interval [CI], 1.06-1.12; P = 9.67 × 10-10) and acetate (OR, 1.24; 95% CI, 1.13-1.37; P = 1.35 × 10-5). In the phenome-wide MR analysis, lowering HDL-C might have deleterious effects on the risk of the circulatory system and foreign body injury, while lowering acetate had deleterious effects on mental disorders disease.The present systematic MR analysis revealed that HDL-C and acetate may be the causal mediators in the risk of developing breast cancer. Side-effect profiles were characterized to help inform drug target prioritization for breast cancer prevention. HDL-C and acetate might be promising drug targets for preventing breast cancer, but they should be applied under weighting advantages and disadvantages.CONCLUSIONSThe present systematic MR analysis revealed that HDL-C and acetate may be the causal mediators in the risk of developing breast cancer. Side-effect profiles were characterized to help inform drug target prioritization for breast cancer prevention. HDL-C and acetate might be promising drug targets for preventing breast cancer, but they should be applied under weighting advantages and disadvantages.
Background Breast cancer is the most common cancer among women with limited treatment options. To identify promising drug targets for breast cancer, we conducted a systematical Mendelian randomization (MR) study to screen blood metabolome for potential causal mediators of breast cancer and further predict target-mediated side effects. Methods We selected 112 unique blood metabolites from 3 large-scale European ancestry-based genome-wide association studies (GWASs) with a total of 147,827 participants. Breast cancer data were obtained from a GWAS in the Breast Cancer Association Consortium (BCAC), involving 122,977 cases and 105,974 controls of European ancestry. We conducted MR analyses to systematically assess the associations of blood metabolites with breast cancer, and a phenome-wide MR analysis was further applied to ascertain the potential on-target side effects of metabolite interventions. Results Two blood metabolites were identified as the potential causal mediators for breast cancer, including high-density lipoprotein cholesterol (HDL-C) (odds ratio [OR], 1.09; 95% confidence interval [CI], 1.06-1.12; P = 9.67 x 10.sup.-10) and acetate (OR, 1.24; 95% CI, 1.13-1.37; P = 1.35 x 10.sup.-5). In the phenome-wide MR analysis, lowering HDL-C might have deleterious effects on the risk of the circulatory system and foreign body injury, while lowering acetate had deleterious effects on mental disorders disease. Conclusions The present systematic MR analysis revealed that HDL-C and acetate may be the causal mediators in the risk of developing breast cancer. Side-effect profiles were characterized to help inform drug target prioritization for breast cancer prevention. HDL-C and acetate might be promising drug targets for preventing breast cancer, but they should be applied under weighting advantages and disadvantages. Keywords: Breast cancer, Metabolites, Mendelian randomization
ArticleNumber 9
Audience Academic
Author Sun, Lulu
Wang, Aili
Zhu, Zhengbao
Wang, Yu
Jia, Yiming
Yang, Pinni
Liu, Fanghua
Chen, Guo-Chong
Guo, Daoxia
Zhang, Yonghong
Shi, Mengyao
Author_xml – sequence: 1
  givenname: Yu
  surname: Wang
  fullname: Wang, Yu
– sequence: 2
  givenname: Fanghua
  surname: Liu
  fullname: Liu, Fanghua
– sequence: 3
  givenname: Lulu
  surname: Sun
  fullname: Sun, Lulu
– sequence: 4
  givenname: Yiming
  surname: Jia
  fullname: Jia, Yiming
– sequence: 5
  givenname: Pinni
  surname: Yang
  fullname: Yang, Pinni
– sequence: 6
  givenname: Daoxia
  surname: Guo
  fullname: Guo, Daoxia
– sequence: 7
  givenname: Mengyao
  surname: Shi
  fullname: Shi, Mengyao
– sequence: 8
  givenname: Aili
  surname: Wang
  fullname: Wang, Aili
– sequence: 9
  givenname: Guo-Chong
  surname: Chen
  fullname: Chen, Guo-Chong
– sequence: 10
  givenname: Yonghong
  surname: Zhang
  fullname: Zhang, Yonghong
– sequence: 11
  givenname: Zhengbao
  surname: Zhu
  fullname: Zhu, Zhengbao
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36694207$$D View this record in MEDLINE/PubMed
BookMark eNp9kk9vFCEYxompse3qF_BgJvHiZSow_JuLyaZR26SJF028EWBedllnoMKsxm8vu1trtzECCQz83md4Zp5zdBJTBIReEnxBiBJvC-kwVy2mXYuJwH3LnqAzwgRvOaNfTx6sT9F5KRuMiVRcPUOnnRA9o1ieoatlKckFM4cUGwvzT4DYrLeTqU9jSkMzwWxsGtMEjYlDM6-hyaF8a5JvbAZT5saZ6CA_R0-9GQu8uJsX6MuH958vr9qbTx-vL5c3reOim9uB0X4AwYnyAL7rrJLGMyIZ8f0gbU-rJWvr6JVUjBspuMPCK1-tdMrzboGuD7pDMht9m8Nk8i-dTND7jZRX2uQ5uBG0BQLe9kIMxDHqe2OokNRiaZTjxOOq9e6gdbu1EwwO4pzNeCR6fBLDWq_SD10vRxkmVeDNnUBO37dQZj2F4mAcTYS0LZpK0fOeivqLFuj1I3STtjnWT1Wp2lRlu7_UylQDIfpU3-t2onopO8YZ4WpHXfyDqn2AKbgaEh_q_lHBq4dG7x3-yUEF6AFwOZWSwd8jBOtd2PQhbLo60fuwaVaL1KMiF-Z9kup1wvi_0t8ygda-
CitedBy_id crossref_primary_10_3389_fgene_2024_1333454
crossref_primary_10_1007_s10528_024_10966_4
crossref_primary_10_1080_2314808X_2024_2355735
crossref_primary_10_3389_fendo_2024_1413777
crossref_primary_10_1038_s41598_024_73337_4
crossref_primary_10_3390_metabo14060322
crossref_primary_10_1371_journal_pone_0304574
crossref_primary_10_2174_0113862073290567240506162553
crossref_primary_10_1016_j_intimp_2024_113593
crossref_primary_10_1186_s12885_024_12908_0
crossref_primary_10_1007_s00240_024_01545_8
crossref_primary_10_2478_ahem_2004_0007
crossref_primary_10_1186_s41065_025_00408_5
crossref_primary_10_1016_j_taap_2024_116855
crossref_primary_10_3390_cells14010005
crossref_primary_10_1002_pmic_202300359
crossref_primary_10_3390_nu16213674
crossref_primary_10_3389_fgene_2024_1385293
crossref_primary_10_1097_MD_0000000000037085
crossref_primary_10_1200_JCO_22_02754
Cites_doi 10.1016/0741-8329(85)90090-4
10.2967/jnumed.115.157834
10.1038/nrm.2016.25
10.1161/CIRCRESAHA.118.311342
10.1007/s11306-021-01823-1
10.1093/ije/dyt179
10.1002/gepi.21758
10.1038/ng.2982
10.1093/ije/dyg070
10.1186/s12916-017-0976-4
10.1007/s00392-017-1106-1
10.1038/nrc.2016.87
10.1007/s10549-019-05165-4
10.3390/metabo11100687
10.1038/ncomms11122
10.1093/hmg/ddy163
10.1161/CIRCRESAHA.117.311002
10.1002/cncr.32802
10.1038/nrclinonc.2017.1
10.1186/s13045-019-0828-0
10.1111/bju.12279
10.1016/j.annonc.2020.01.066
10.1038/s41588-018-0184-y
10.3390/jcm9092846
10.1016/j.ccell.2014.12.002
10.1016/j.jacc.2016.09.972
10.1038/nature24284
10.7554/eLife.34408
10.1161/CIRCULATIONAHA.119.040180
10.1080/19490976.2015.1134082
10.1097/RLU.0b013e3181bed06e
10.1158/1078-0432.CCR-11-0817
10.1038/ng.3314
10.3322/caac.21660
10.1093/ije/dyz242
10.3322/caac.21654
10.1002/gepi.21965
10.1136/bmj.k3225
10.1093/jn/nxz268
ContentType Journal Article
Copyright 2023. The Author(s).
COPYRIGHT 2023 BioMed Central Ltd.
2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2023
Copyright_xml – notice: 2023. The Author(s).
– notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2023
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TO
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s13058-023-01609-4
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE

Publicly Available Content Database
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1465-542X
EndPage 11
ExternalDocumentID oai_doaj_org_article_be1efb966d1c42f9aa2672b07a8c51f0
PMC9872401
A734541583
36694207
10_1186_s13058_023_01609_4
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations United Kingdom--UK
GeographicLocations_xml – name: United Kingdom--UK
GrantInformation_xml – fundername: Natural Science Research Project of Jiangsu Provincial Higher Education
  grantid: 21KJB330006
– fundername: National Natural Science Foundation of China
  grantid: 82020108028
– fundername: National Natural Science Foundation of China
  grantid: 82103917
– fundername: ;
  grantid: 21KJB330006
– fundername: ;
  grantid: 82020108028; 82103917
GroupedDBID ---
04C
0R~
23N
2WC
4.4
53G
5GY
5VS
6J9
7X7
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABUWG
ACGFO
ACGFS
ACJQM
ACMJI
ACPRK
ADBBV
ADFRT
ADUKV
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIAM
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BMSDO
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
EIHBH
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
ICW
IHR
INH
INR
ITC
KQ8
O5R
O5S
OK1
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RBZ
ROL
RPM
RSV
SBL
SOJ
TR2
U2A
UKHRP
WOQ
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
3V.
7TO
7XB
8FK
AZQEC
DWQXO
H94
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c563t-d429de6518feef33b87af41741f9d7b92305bb5bb987845a765c06f8f46538f53
IEDL.DBID DOA
ISSN 1465-542X
1465-5411
IngestDate Wed Aug 27 01:27:02 EDT 2025
Thu Aug 21 18:38:41 EDT 2025
Fri Jul 11 05:21:43 EDT 2025
Mon Jun 30 03:10:20 EDT 2025
Tue Jun 17 20:17:06 EDT 2025
Tue Jun 10 20:20:00 EDT 2025
Tue Mar 18 09:46:16 EDT 2025
Thu Apr 24 22:53:34 EDT 2025
Tue Jul 01 02:43:15 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Metabolites
Breast cancer
Mendelian randomization
Language English
License 2023. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c563t-d429de6518feef33b87af41741f9d7b92305bb5bb987845a765c06f8f46538f53
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://doaj.org/article/be1efb966d1c42f9aa2672b07a8c51f0
PMID 36694207
PQID 2777782763
PQPubID 2034567
PageCount 11
ParticipantIDs doaj_primary_oai_doaj_org_article_be1efb966d1c42f9aa2672b07a8c51f0
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9872401
proquest_miscellaneous_2769592602
proquest_journals_2777782763
gale_infotracmisc_A734541583
gale_infotracacademiconefile_A734541583
pubmed_primary_36694207
crossref_primary_10_1186_s13058_023_01609_4
crossref_citationtrail_10_1186_s13058_023_01609_4
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-01-24
PublicationDateYYYYMMDD 2023-01-24
PublicationDate_xml – month: 01
  year: 2023
  text: 2023-01-24
  day: 24
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Breast cancer research : BCR
PublicationTitleAlternate Breast Cancer Res
PublicationYear 2023
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References A Beeghly-Fadiel (1609_CR34) 2020; 49
DA Bennett (1609_CR20) 2017; 103
S Burgess (1609_CR25) 2013; 37
N Li (1609_CR2) 2019; 12
CL Silva (1609_CR40) 2021; 17
SY Shin (1609_CR13) 2014; 46
DJ Morrison (1609_CR35) 2016; 7
K Trajanoska (1609_CR29) 2018; 362
J Kettunen (1609_CR14) 2016; 7
N Murphy (1609_CR19) 2020; 31
G Hemani (1609_CR23) 2018; 7
M Chong (1609_CR22) 2019; 140
GD Smith (1609_CR17) 2003; 32
KN Seyed (1609_CR18) 2021; 10
MR Nelson (1609_CR12) 2015; 47
JR Ussher (1609_CR9) 2016; 68
H Sung (1609_CR1) 2021; 71
ZT Schug (1609_CR36) 2016; 16
L Huo (1609_CR42) 2009; 34
SJ Henley (1609_CR3) 2020; 126
RW McGarrah (1609_CR10) 2018; 122
B Pan (1609_CR31) 2012; 18
1609_CR15
ZT Schug (1609_CR41) 2015; 27
J Bowden (1609_CR26) 2016; 40
VA Katzke (1609_CR32) 2017; 15
QWJ Zhao (1609_CR27) 2019; 5
SK Clinton (1609_CR38) 2020; 150
CH Johnson (1609_CR8) 2016; 17
G Hemani (1609_CR28) 2018; 27
H Zhao (1609_CR6) 2019; 176
DK Arnett (1609_CR11) 2018; 122
MJ Brion (1609_CR24) 2013; 42
SM Jung (1609_CR33) 2020; 9
UE Martinez-Outschoorn (1609_CR39) 2017; 14
W März (1609_CR30) 2017; 106
H Nuutinen (1609_CR37) 1985; 2
W Zhou (1609_CR21) 2018; 50
RL Siegel (1609_CR4) 2021; 71
ES McDonald (1609_CR5) 2016; 57
B Mohsen (1609_CR43) 2013; 112
K Michailidou (1609_CR16) 2017; 551
JO Onuh (1609_CR7) 2021; 11
References_xml – volume: 2
  start-page: 623
  issue: 4
  year: 1985
  ident: 1609_CR37
  publication-title: Alcohol (Fayetteville, NY)
  doi: 10.1016/0741-8329(85)90090-4
– volume: 57
  start-page: 9s
  issue: Suppl 1
  year: 2016
  ident: 1609_CR5
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.115.157834
– volume: 17
  start-page: 451
  issue: 7
  year: 2016
  ident: 1609_CR8
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/nrm.2016.25
– volume: 103
  start-page: 1400
  issue: 18
  year: 2017
  ident: 1609_CR20
  publication-title: Heart (British Cardiac Society)
– volume: 122
  start-page: 1409
  issue: 10
  year: 2018
  ident: 1609_CR11
  publication-title: Circ Res
  doi: 10.1161/CIRCRESAHA.118.311342
– volume: 17
  start-page: 72
  issue: 8
  year: 2021
  ident: 1609_CR40
  publication-title: Metabolomics
  doi: 10.1007/s11306-021-01823-1
– volume: 42
  start-page: 1497
  issue: 5
  year: 2013
  ident: 1609_CR24
  publication-title: Int J Epidemiol
  doi: 10.1093/ije/dyt179
– volume: 37
  start-page: 658
  issue: 7
  year: 2013
  ident: 1609_CR25
  publication-title: Genet Epidemiol
  doi: 10.1002/gepi.21758
– volume: 46
  start-page: 543
  issue: 6
  year: 2014
  ident: 1609_CR13
  publication-title: Nat Genet
  doi: 10.1038/ng.2982
– volume: 32
  start-page: 1
  issue: 1
  year: 2003
  ident: 1609_CR17
  publication-title: Int J Epidemiol
  doi: 10.1093/ije/dyg070
– volume: 15
  start-page: 218
  issue: 1
  year: 2017
  ident: 1609_CR32
  publication-title: BMC Med
  doi: 10.1186/s12916-017-0976-4
– volume: 106
  start-page: 663
  issue: 9
  year: 2017
  ident: 1609_CR30
  publication-title: Clin Res Cardiol
  doi: 10.1007/s00392-017-1106-1
– volume: 16
  start-page: 708
  issue: 11
  year: 2016
  ident: 1609_CR36
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc.2016.87
– volume: 176
  start-page: 687
  issue: 3
  year: 2019
  ident: 1609_CR6
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-019-05165-4
– volume: 11
  start-page: 63
  issue: 10
  year: 2021
  ident: 1609_CR7
  publication-title: Metabolites
  doi: 10.3390/metabo11100687
– volume: 7
  start-page: 11122
  year: 2016
  ident: 1609_CR14
  publication-title: Nat Commun
  doi: 10.1038/ncomms11122
– volume: 27
  start-page: R195
  issue: R2
  year: 2018
  ident: 1609_CR28
  publication-title: Hum Mol Genet
  doi: 10.1093/hmg/ddy163
– volume: 122
  start-page: 1238
  issue: 9
  year: 2018
  ident: 1609_CR10
  publication-title: Circ Res
  doi: 10.1161/CIRCRESAHA.117.311002
– volume: 5
  start-page: 78
  year: 2019
  ident: 1609_CR27
  publication-title: arXiv
– volume: 126
  start-page: 2225
  issue: 10
  year: 2020
  ident: 1609_CR3
  publication-title: Cancer
  doi: 10.1002/cncr.32802
– volume: 14
  start-page: 113
  issue: 2
  year: 2017
  ident: 1609_CR39
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/nrclinonc.2017.1
– volume: 12
  start-page: 140
  issue: 1
  year: 2019
  ident: 1609_CR2
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-019-0828-0
– volume: 112
  start-page: 1062
  issue: 8
  year: 2013
  ident: 1609_CR43
  publication-title: BJU Int
  doi: 10.1111/bju.12279
– volume: 31
  start-page: 641
  issue: 5
  year: 2020
  ident: 1609_CR19
  publication-title: Ann Oncol
  doi: 10.1016/j.annonc.2020.01.066
– volume: 50
  start-page: 1335
  issue: 9
  year: 2018
  ident: 1609_CR21
  publication-title: Nat Genet
  doi: 10.1038/s41588-018-0184-y
– volume: 9
  start-page: 53
  issue: 9
  year: 2020
  ident: 1609_CR33
  publication-title: J Clin Med
  doi: 10.3390/jcm9092846
– volume: 27
  start-page: 57
  issue: 1
  year: 2015
  ident: 1609_CR41
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2014.12.002
– volume: 68
  start-page: 2850
  issue: 25
  year: 2016
  ident: 1609_CR9
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2016.09.972
– volume: 551
  start-page: 92
  issue: 7678
  year: 2017
  ident: 1609_CR16
  publication-title: Nature
  doi: 10.1038/nature24284
– volume: 7
  start-page: 80
  year: 2018
  ident: 1609_CR23
  publication-title: eLife
  doi: 10.7554/eLife.34408
– volume: 140
  start-page: 819
  issue: 10
  year: 2019
  ident: 1609_CR22
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.119.040180
– volume: 7
  start-page: 189
  issue: 3
  year: 2016
  ident: 1609_CR35
  publication-title: Gut microbes
  doi: 10.1080/19490976.2015.1134082
– volume: 34
  start-page: 874
  issue: 12
  year: 2009
  ident: 1609_CR42
  publication-title: Clin Nucl Med
  doi: 10.1097/RLU.0b013e3181bed06e
– volume: 18
  start-page: 1246
  issue: 5
  year: 2012
  ident: 1609_CR31
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-11-0817
– volume: 47
  start-page: 856
  issue: 8
  year: 2015
  ident: 1609_CR12
  publication-title: Nat Genet
  doi: 10.1038/ng.3314
– volume: 71
  start-page: 209
  issue: 3
  year: 2021
  ident: 1609_CR1
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21660
– volume: 49
  start-page: 1117
  issue: 4
  year: 2020
  ident: 1609_CR34
  publication-title: Int J Epidemiol
  doi: 10.1093/ije/dyz242
– volume: 10
  start-page: 52
  issue: 2
  year: 2021
  ident: 1609_CR18
  publication-title: Cells
– volume: 71
  start-page: 7
  issue: 1
  year: 2021
  ident: 1609_CR4
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21654
– volume: 40
  start-page: 304
  issue: 4
  year: 2016
  ident: 1609_CR26
  publication-title: Genet Epidemiol
  doi: 10.1002/gepi.21965
– ident: 1609_CR15
– volume: 362
  start-page: k3225
  year: 2018
  ident: 1609_CR29
  publication-title: BMJ (Clinical research ed)
  doi: 10.1136/bmj.k3225
– volume: 150
  start-page: 663
  issue: 4
  year: 2020
  ident: 1609_CR38
  publication-title: J Nutr
  doi: 10.1093/jn/nxz268
SSID ssj0017858
Score 2.4982595
Snippet Breast cancer is the most common cancer among women with limited treatment options. To identify promising drug targets for breast cancer, we conducted a...
Background Breast cancer is the most common cancer among women with limited treatment options. To identify promising drug targets for breast cancer, we...
BackgroundBreast cancer is the most common cancer among women with limited treatment options. To identify promising drug targets for breast cancer, we...
Abstract Background Breast cancer is the most common cancer among women with limited treatment options. To identify promising drug targets for breast cancer,...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 9
SubjectTerms Acetates
Acetic acid
Biobanks
Biomarkers
Blood
Breast cancer
Breast Neoplasms - etiology
Breast Neoplasms - genetics
Cancer
Cancer therapies
Care and treatment
Cholesterol
Cholesterol, HDL - genetics
Circulatory system
Clinical trials
Collaboration
Consortia
Development and progression
Disease
Female
Genome-wide association studies
Genome-Wide Association Study
Genomes
Genomics
Health aspects
High density lipoprotein
Humans
Mendelian randomization
Mental disorders
Mental illness
Metabolism
Metabolites
Metabolome
NMR
Nuclear magnetic resonance
Oncology, Experimental
Polymorphism, Single Nucleotide
Prevention
Risk Factors
Side effects
Statistical power
Therapeutic targets
Triglycerides
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Ni9QwFA-6gngR3fWjukoE0YOEbdJ89SSjuAzCenJhbqH5UmGnXWe6B_97X9LMOEXY0lOTQtP3_fLyewi9Da3w8O8DobRzhHvrieYuEBlSwqGWbcwJt4tvcnnJv67EqiTctqWscqcTs6L2g0s58jOm4NIMxOHj9W-Sukal3dXSQuMuupegy1JJl1rtA67UeF5Pp4sEEZzS3aEZLc-2oLuFJmCxSMJYawmfGaaM3_-_lj4wU_MSygObdP4IPSzOJF5M1H-M7oT-GJ0segik13_wO5zLO3Pe_Bjdvyi76CdoeUATXAq1cG7Wh3MdO16HEXjjalgH3PUeg4-IUwk6HiK2qYh9xC4xy-YJujz_8v3zkpSOCsQJ2YzEg_XxQQqqYwixaaxWXeQQlNDYemXB2auFtXC3WmkuOiWFq2XUMaGw6Siap-ioH_rwHGFRO-G7mjmgLzgFVifUmBCl44K5wH2F6O53GlfgxlPXiyuTww4tzUQCAyQwmQSGV-jD_p3rCWzj1tmfEpX2MxNQdn4wbH6YInfGBhqihZjOU8dZbLuOScVsrTrtBI11hd4nGpskzvB5riunEmCRCRjLLFTDgXWEbip0OpsJYujmwzsuMUUNbM0_pq3Qm_1wejOVtvVhuElzZCtaCCtZhZ5NTLVfUiNly1mtKqRm7DZb83yk__Uzg4QDBcFZoy9u_6yX6AGbZIAwfoqOxs1NeAVe1mhfZ1H6C-NZIhY
  priority: 102
  providerName: ProQuest
Title Association between human blood metabolome and the risk of breast cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/36694207
https://www.proquest.com/docview/2777782763
https://www.proquest.com/docview/2769592602
https://pubmed.ncbi.nlm.nih.gov/PMC9872401
https://doaj.org/article/be1efb966d1c42f9aa2672b07a8c51f0
Volume 25
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Ni9QwFH_oCuJFdNeP6jpEED1I2DbNV48zsssg7CKLC4OX0HyhsNOR3e7B_96XtDNMEfRiKT00CSTvI--95OUXgHehER5pH2hVtY5ybz3V3AUqQ1pwKGUT84Lb-YVcXvHPK7Hau-or5YQN8MAD4U5sqEK06JT7ynEWm7ZlUjFbqlY7UcUcraPN2wZT4_6B0kJvj8hoeXKLM7XQFO0TTYhqDeUTM5TR-v-ck_eM0jRhcs8CnT2Bx6PrSOZDl5_CvdAdwtG8w7B5_Yu8JzmZM6-SH8LD83HP_AiWexwgY1oWyVfzkZy1TtahR0m43qwDaTtP0CMkKeGcbCKxKWW9Jy6Jxs0zuDo7_fppScf7E6gTsu6pR1vjgxSVjiHEurZatZFjCFLFxiuLrl0prMW30Upz0SopXCmjjglzTUdRP4eDbtOFl0BE6YRvS-aQm-gCWJ0wYkKUjgvmAvcFVFtyGjeCi6c7Lq5NDjK0NAMLDLLAZBYYXsDHXZufA7TGX2svEpd2NRMsdv6BwmJGYTH_EpYCPiQem6S82D3XjmcQcJAJBsvMVc0FujS6LuB4UhOVzk2Lt1JiRqW_NUzhoxnO2AW83RWnlimRrQubu1RHNqLBIJIV8GIQqt2QaikbzkpVgJqI22TM05Lux_cMCY4cRNesevU_iPQaHrFBUyjjx3DQ39yFN-h59XYG99VKzeDB4vTiy-Usqxx-LxfffgO_VCz6
linkProvider Directory of Open Access Journals
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB5VWwm4IGh5BAoYiccBWU0c23EOCG2h1ZZ2Vwi1Um8mcWxA6iZldyvUP8VvZOxkl42QemuUU2xLseeblz2eAXhlc1Hh2luaJIWhvCorqrixVFq_4RDL3IUNt_FEjk755zNxtgF_lndhfFjlUiYGQV01xu-R77IMH8WQHT5c_KK-apQ_XV2W0GhhcWSvfqPLNn9_-Anp-5qxg_2TjyPaVRWgRsh0QSuUwJWVIlHOWpempcoKx9EwT1xeZSUaPLEoS3zRG1dcFJkUJpZOOZ-JTDlfJQJF_iZP0ZUZwObe_uTL19W5RaZCRVAUP4IKniTLazpK7s5RWwhFUUdSn9Utp7ynCkPFgP_1wppi7AdtrmnBg3twtzNfybDF233YsPUWbA9rdN2nV-QNCQGlYad-C26Nu3P7bRitoYB0oWEklAckIXKeTO0C0XjeTC0p6oqgVUp80DtpHCl92PyCGA_P2QM4vZHVfgiDuqntYyAiNqIqYmYQUWiGlMrnqbFOGi6YsbyKIFkupzZdgnNfZ-NcB0dHSd2SQCMJdCCB5hG8W425aNN7XNt7z1Np1dOn5g4fmtl33XG6Lm1iXYleZJUYzlxeFExmrIyzQhmRuDiCt57G2gsQ_D1TdPcgcJI-FZceZilH6AiVRrDT64mMb_rNS5ToTvDM9T82ieDlqtmP9MF0tW0ufR-ZixwdWRbBoxZUqymlUuacxVkEWQ9uvTn3W-qfP0JacqQgmofJk-t_6wXcHp2Mj_Xx4eToKdxhLT9QxndgsJhd2mdo4y3K5x1jEfh207z8F6oeX7M
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Association+between+human+blood+metabolome+and+the+risk+of+breast+cancer&rft.jtitle=Breast+cancer+research+%3A+BCR&rft.au=Wang%2C+Yu&rft.au=Liu%2C+Fanghua&rft.au=Sun%2C+Lulu&rft.au=Jia%2C+Yiming&rft.date=2023-01-24&rft.pub=BioMed+Central+Ltd&rft.issn=1465-5411&rft.volume=25&rft.issue=1&rft_id=info:doi/10.1186%2Fs13058-023-01609-4&rft.externalDocID=A734541583
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1465-542X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1465-542X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1465-542X&client=summon